Bharat Biotech: Difference between revisions

Coordinates: 17°39′55″N 78°36′17″E / 17.6652°N 78.6047°E / 17.6652; 78.6047
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
removed as per WP:NOTNEWS policy
Tags: Manual revert references removed
No edit summary
Tags: Reverted Visual edit Mobile edit Mobile web edit
Line 37: Line 37:
{{see also|Covaxin|BBV154|COVID-19 vaccine}}
{{see also|Covaxin|BBV154|COVID-19 vaccine}}


In April 2020, the company announced that they have partnered with US-based company FluGen and [[University of Wisconsin-Madison]] to develop a COVID-19 vaccine.<ref>{{cite web |title=UW-Madison, Flugen, Bharat Biotech to develop coroflu, a coronavirus vaccine |url=https://ghi.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/ |website=Global Health Institute |access-date=30 June 2020 |archive-date=10 February 2021 |archive-url=https://web.archive.org/web/20210210135626/https://ghi.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/ |url-status=live }}</ref><ref>{{cite news |title=Bharat Biotech ties up with US varsity for Covid vaccine |url=https://www.hindustantimes.com/india-news/bharat-biotech-ties-up-with-us-varsity-for-covid-vaccine/story-dyJPOzW2G2rXcwsa9XV3tL.html |work=Hindustan Times |date=20 May 2020 |language=en |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503092950/https://www.hindustantimes.com/india-news/bharat-biotech-ties-up-with-us-varsity-for-covid-vaccine/story-dyJPOzW2G2rXcwsa9XV3tL.html |url-status=live }}</ref>
[[File:Bharat Biotech Covaxin Bangalore BESTpedia.jpg|thumb|A 5ml vial of Covaxin]]
[[File:Bharat Biotech Covaxin Bangalore BESTpedia.jpg|thumb|A 5ml vial of Covaxin]]
In May 2020, Indian Council of Medical Research's ([[ICMR]]'s) [[National Institute of Virology]] approved and provided the virus strains for developing a fully indigenous [[COVID-19]] vaccine.<ref>{{cite news |title=ICMR teams up with Bharat Biotech to develop Covid-19 vaccine |url=https://www.livemint.com/news/india/icmr-teams-up-with-bharat-biotech-to-develop-covid-19-vaccine-11589038719666.html |work=Livemint |date=9 May 2020 |language=en |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503071056/https://www.livemint.com/news/india/icmr-teams-up-with-bharat-biotech-to-develop-covid-19-vaccine-11589038719666.html |url-status=live }}</ref><ref>{{cite news |last1=Chakrabarti |first1=Angana |title=India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech |url=https://theprint.in/health/india-to-develop-fully-indigenous-covid-vaccine-as-icmr-partners-with-bharat-biotech/418180/ |work=ThePrint |date=10 May 2020 |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503084559/https://theprint.in/health/india-to-develop-fully-indigenous-covid-vaccine-as-icmr-partners-with-bharat-biotech/418180/ |url-status=live }}</ref> On June 29, 2020, the company got permission to conduct Phase 1 and Phase 2 [[clinical trials in India]] for a developmental [[COVID-19]] vaccine named '''[[Covaxin]]''', from the Drugs Controller General of India ([[DCGI]]), [[Government of India]].<ref>{{cite news |title=India's First COVID-19 Vaccine Candidate Approved for Human Trials |url=https://www.nytimes.com/reuters/2020/06/29/world/asia/29reuters-health-coronavirus-india-vaccine.html |work=The New York Times |date=29 June 2020 |access-date=30 June 2020 |archive-date=2 July 2020 |archive-url=https://web.archive.org/web/20200702105140/https://www.nytimes.com/reuters/2020/06/29/world/asia/29reuters-health-coronavirus-india-vaccine.html |url-status=live }}</ref><ref>{{cite news |title=Human trial of India coronavirus vaccine announced |url=https://www.bbc.com/news/world-asia-india-53230607 |work=BBC News |date=30 June 2020 |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503140832/https://www.bbc.com/news/world-asia-india-53230607 |url-status=live }}</ref><ref>{{cite news |title=Bharat Biotech's Covid vaccine 1st in India to get approval for human trials |url=https://indianexpress.com/article/india/bharat-biotechs-covid-vaccine-1st-in-india-to-get-approval-for-human-trials-6482403/ |work=The Indian Express |date=30 June 2020 |language=en |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503123154/https://indianexpress.com/article/india/bharat-biotechs-covid-vaccine-1st-in-india-to-get-approval-for-human-trials-6482403/ |url-status=live }}</ref><ref>{{cite news |title=Covaxin: India's first COVID19 vaccine candidate from Bharat Biotech to begin human trials; check details |url=https://www.financialexpress.com/lifestyle/health/covaxin-bharat-biotech-coronavirus-vaccine-india-first-covid19-vaccine-latest-updates/2008500/ |work=The Financial Express |date=30 June 2020 |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503110420/https://www.financialexpress.com/lifestyle/health/covaxin-bharat-biotech-coronavirus-vaccine-india-first-covid19-vaccine-latest-updates/2008500/ |url-status=live }}</ref> The Central Drugs Laboratory (CDL) at Kasauli in Himachal Pradesh has been engaged in testing experimental batches of Bharat Biotech's COVID-19 vaccine Covaxin on a priority basis.<ref>{{cite news |title=Bharat Biotech COVID-19 vaccine: Testing underway at CDL-Kasauli, volunteer enrolment begins |url=https://www.moneycontrol.com/news/trends/health-trends/bharat-biotech-covid-19-vaccine-testing-underway-at-cdl-kasauli-volunteer-enrolment-begins-5529041.html |work=Moneycontrol |access-date=10 July 2020 |archive-date=10 July 2020 |archive-url=https://web.archive.org/web/20200710182158/https://www.moneycontrol.com/news/trends/health-trends/bharat-biotech-covid-19-vaccine-testing-underway-at-cdl-kasauli-volunteer-enrolment-begins-5529041.html |url-status=live }}</ref> A total of 12 sites were selected by the [[Indian Council for Medical Research]] for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate.<ref>{{cite news |title=Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS |url=http://ddnews.gov.in/health/human-clinical-trials-potential-covid-19-vaccine-%E2%80%98covaxin%E2%80%99-started-aiims |work=DD News |publisher=Prasar Bharati, Ministry of I & B, Government of India |date=25 July 2020 |access-date=7 August 2020 |archive-date=24 January 2021 |archive-url=https://web.archive.org/web/20210124153146/http://ddnews.gov.in/health/human-clinical-trials-potential-covid-19-vaccine-%E2%80%98covaxin%E2%80%99-started-aiims |url-status=live }}</ref><ref>{{cite news |title=Delhi: 30-year-old is first to get dose of trial drug Covaxin |url=https://indianexpress.com/article/india/aiims-administers-first-dose-of-bharat-biotechs-potential-covid-vaccine-to-30-yr-old-man-6521778/ |work=The Indian Express |date=25 July 2020 |language=en |access-date=7 August 2020 |archive-date=16 March 2021 |archive-url=https://web.archive.org/web/20210316225319/https://indianexpress.com/article/india/aiims-administers-first-dose-of-bharat-biotechs-potential-covid-vaccine-to-30-yr-old-man-6521778/ |url-status=live }}</ref>
In May 2020, Indian Council of Medical Research's ([[ICMR]]'s) [[National Institute of Virology]] approved and provided the virus strains for developing a fully indigenous [[COVID-19]] vaccine.<ref>{{cite news |title=ICMR teams up with Bharat Biotech to develop Covid-19 vaccine |url=https://www.livemint.com/news/india/icmr-teams-up-with-bharat-biotech-to-develop-covid-19-vaccine-11589038719666.html |work=Livemint |date=9 May 2020 |language=en |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503071056/https://www.livemint.com/news/india/icmr-teams-up-with-bharat-biotech-to-develop-covid-19-vaccine-11589038719666.html |url-status=live }}</ref><ref>{{cite news |last1=Chakrabarti |first1=Angana |title=India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech |url=https://theprint.in/health/india-to-develop-fully-indigenous-covid-vaccine-as-icmr-partners-with-bharat-biotech/418180/ |work=ThePrint |date=10 May 2020 |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503084559/https://theprint.in/health/india-to-develop-fully-indigenous-covid-vaccine-as-icmr-partners-with-bharat-biotech/418180/ |url-status=live }}</ref> On June 29, 2020, the company got permission to conduct Phase 1 and Phase 2 [[clinical trials in India]] for a developmental [[COVID-19]] vaccine named '''[[Covaxin]]''', from the Drugs Controller General of India ([[DCGI]]), [[Government of India]].<ref>{{cite news |title=India's First COVID-19 Vaccine Candidate Approved for Human Trials |url=https://www.nytimes.com/reuters/2020/06/29/world/asia/29reuters-health-coronavirus-india-vaccine.html |work=The New York Times |date=29 June 2020 |access-date=30 June 2020 |archive-date=2 July 2020 |archive-url=https://web.archive.org/web/20200702105140/https://www.nytimes.com/reuters/2020/06/29/world/asia/29reuters-health-coronavirus-india-vaccine.html |url-status=live }}</ref><ref>{{cite news |title=Human trial of India coronavirus vaccine announced |url=https://www.bbc.com/news/world-asia-india-53230607 |work=BBC News |date=30 June 2020 |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503140832/https://www.bbc.com/news/world-asia-india-53230607 |url-status=live }}</ref><ref>{{cite news |title=Bharat Biotech's Covid vaccine 1st in India to get approval for human trials |url=https://indianexpress.com/article/india/bharat-biotechs-covid-vaccine-1st-in-india-to-get-approval-for-human-trials-6482403/ |work=The Indian Express |date=30 June 2020 |language=en |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503123154/https://indianexpress.com/article/india/bharat-biotechs-covid-vaccine-1st-in-india-to-get-approval-for-human-trials-6482403/ |url-status=live }}</ref><ref>{{cite news |title=Covaxin: India's first COVID19 vaccine candidate from Bharat Biotech to begin human trials; check details |url=https://www.financialexpress.com/lifestyle/health/covaxin-bharat-biotech-coronavirus-vaccine-india-first-covid19-vaccine-latest-updates/2008500/ |work=The Financial Express |date=30 June 2020 |access-date=30 June 2020 |archive-date=3 May 2021 |archive-url=https://web.archive.org/web/20210503110420/https://www.financialexpress.com/lifestyle/health/covaxin-bharat-biotech-coronavirus-vaccine-india-first-covid19-vaccine-latest-updates/2008500/ |url-status=live }}</ref> The Central Drugs Laboratory (CDL) at Kasauli in Himachal Pradesh has been engaged in testing experimental batches of Bharat Biotech's COVID-19 vaccine Covaxin on a priority basis.<ref>{{cite news |title=Bharat Biotech COVID-19 vaccine: Testing underway at CDL-Kasauli, volunteer enrolment begins |url=https://www.moneycontrol.com/news/trends/health-trends/bharat-biotech-covid-19-vaccine-testing-underway-at-cdl-kasauli-volunteer-enrolment-begins-5529041.html |work=Moneycontrol |access-date=10 July 2020 |archive-date=10 July 2020 |archive-url=https://web.archive.org/web/20200710182158/https://www.moneycontrol.com/news/trends/health-trends/bharat-biotech-covid-19-vaccine-testing-underway-at-cdl-kasauli-volunteer-enrolment-begins-5529041.html |url-status=live }}</ref> A total of 12 sites were selected by the [[Indian Council for Medical Research]] for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate.<ref>{{cite news |title=Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS |url=http://ddnews.gov.in/health/human-clinical-trials-potential-covid-19-vaccine-%E2%80%98covaxin%E2%80%99-started-aiims |work=DD News |publisher=Prasar Bharati, Ministry of I & B, Government of India |date=25 July 2020 |access-date=7 August 2020 |archive-date=24 January 2021 |archive-url=https://web.archive.org/web/20210124153146/http://ddnews.gov.in/health/human-clinical-trials-potential-covid-19-vaccine-%E2%80%98covaxin%E2%80%99-started-aiims |url-status=live }}</ref><ref>{{cite news |title=Delhi: 30-year-old is first to get dose of trial drug Covaxin |url=https://indianexpress.com/article/india/aiims-administers-first-dose-of-bharat-biotechs-potential-covid-vaccine-to-30-yr-old-man-6521778/ |work=The Indian Express |date=25 July 2020 |language=en |access-date=7 August 2020 |archive-date=16 March 2021 |archive-url=https://web.archive.org/web/20210316225319/https://indianexpress.com/article/india/aiims-administers-first-dose-of-bharat-biotechs-potential-covid-vaccine-to-30-yr-old-man-6521778/ |url-status=live }}</ref>

Revision as of 17:16, 3 November 2021

17°39′55″N 78°36′17″E / 17.6652°N 78.6047°E / 17.6652; 78.6047

Bharat Biotech International Limited
Company typePrivate Limited Company
IndustryBiotechnology
Founded1996; 28 years ago (1996)
FounderKrishna Ella
HeadquartersGenome Valley, Turakapally, Hyderabad
Area served
Worldwide
Key people
Krishna Ella
(Chairman & MD)
Products
SubsidiariesChiron Behring Vaccines [3]
Websitewww.bharatbiotech.com

Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in Hyderabad, engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.[4]

Overview

Bharat Biotech has its manufacturing facility situated at Genome Valley, Hyderabad, India.[4] As of July 2020, the company has over 700 employees[5] and has a presence worldwide.[4]

The company has been responsible for developing an eco-friendly recombinant[6] and a naturally attenuated strain derived Rotavirus vaccine called ROTAVAC.[7][8] They were one of the first to develop vaccines for viral diseases like Chikungunya[9][10] and Zika.[11][12] The company also produces vaccines for Japanese Encephalitis.[13] Bharat Biotech has biosafety level 3 (BSL3) laboratories.[14]

COVID-19 vaccine development

See also: Covaxin, BBV154, and COVID-19 vaccine
A 5ml vial of Covaxin

In May 2020, Indian Council of Medical Research's (ICMR's) National Institute of Virology approved and provided the virus strains for developing a fully indigenous COVID-19 vaccine.[15][16] On June 29, 2020, the company got permission to conduct Phase 1 and Phase 2 clinical trials in India for a developmental COVID-19 vaccine named Covaxin, from the Drugs Controller General of India (DCGI), Government of India.[17][18][19][20] The Central Drugs Laboratory (CDL) at Kasauli in Himachal Pradesh has been engaged in testing experimental batches of Bharat Biotech's COVID-19 vaccine Covaxin on a priority basis.[21] A total of 12 sites were selected by the Indian Council for Medical Research for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate.[22][23]

In September 2020, the company announced that it was going to manufacture the novel chimp-adenovirus, a single dose intranasal vaccine (codenamed BBV154) for COVID-19 being developed in collaboration with the American company Precision virologics[24] and Washington University School of Medicine in St Louis, Missouri. It is currently undergoing clinical trials.[25][26] On October 12 2021, Bharat Biotech's Covaxin got approved for usage on children between 2 to 18 years of age. [27]

Attempted data theft

In March 2021, Reuters reported that Chinese state-backed cyber-espionage group Red Apollo targeted Bharat Biotech's intellectual property for exfiltration.[28]

See also

References

  1. ^ "WHO prequalifies new rotavirus vaccine". WHO. Archived from the original on 17 July 2020. Retrieved 2 July 2020.
  2. ^ "WHO recommends use of first typhoid conjugate vaccine". WHO. Archived from the original on 7 September 2018. Retrieved 2 July 2020.
  3. ^ "Bharat Biotech buys Chiron Behring Vaccines from GSK". The Hindu BusinessLine. Archived from the original on 31 August 2020. Retrieved 1 July 2020.
  4. ^ a b c "Bharat Biotech International Ltd". www.bloomberg.com. Archived from the original on 16 November 2020. Retrieved 3 July 2020.
  5. ^ "Leading Biotech Vaccine Manufacturers in India - Bharat Biotech". www.bharatbiotech.com. Archived from the original on 5 July 2020. Retrieved 30 June 2020.
  6. ^ "Process for the preparation and purification of recombinant proteins". patents.google.com. US patent No US8956812B2. 23 August 2004. Archived from the original on 9 May 2021. Retrieved 30 June 2020.
  7. ^ Bhandari, Nita; Rongsen-Chandola, Temsunaro; Bavdekar, Ashish; John, Jacob; Antony, Kalpana; Taneja, Sunita; Goyal, Nidhi; Kawade, Anand; Kang, Gagandeep; Rathore, Sudeep Singh; Juvekar, Sanjay; Muliyil, Jayaprakash; Arya, Alok; Shaikh, Hanif; Abraham, Vinod; Vrati, Sudhanshu; Proschan, Michael; Kohberger, Robert; Thiry, Georges; Glass, Roger; Greenberg, Harry B; Curlin, George; Mohan, Krishna; Harshavardhan, G V J A; Prasad, Sai; Rao, T S; Boslego, John; Bhan, Maharaj Kishan (June 2014). "Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial". The Lancet. 383 (9935): 2136–2143. doi:10.1016/S0140-6736(13)62630-6. PMC 4532697. PMID 24629994.
  8. ^ Kang, G (October 2006). "Rotavirus vaccines". Indian Journal of Medical Microbiology. 24 (4): 252–7. doi:10.4103/0255-0857.29382. PMC 2481304. PMID 17185842.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  9. ^ "Bharat Biotech's Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market". Moneycontrol. Archived from the original on 30 June 2020. Retrieved 30 June 2020.
  10. ^ "CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원". CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원 - 뉴스와이어 (in Korean). 3 June 2020.
  11. ^ "Bharat Biotech gets breakthrough in developing Zika vaccine". The Economic Times. 4 February 2016. Archived from the original on 9 May 2021. Retrieved 30 June 2020.
  12. ^ "CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI – IVI". www.ivi.int. International Vaccine Institute. Archived from the original on 24 September 2020. Retrieved 30 June 2020.
  13. ^ Singh, Anit; Mitra, Monjori; Sampath, Gadey; Venugopal, P.; Rao, J. Venkateswara; Krishnamurthy, B.; Gupta, Mukesh Kumar; Sri Krishna, S.; Sudhakar, B.; Rao, N. Bhuvaneswara; Kaushik, Yashpal; Gopinathan, K.; Hegde, Nagendra R.; Gore, Milind M.; Krishna Mohan, V.; Ella, Krishna M. (1 September 2015). "A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains". Journal of Infectious Diseases. 212 (5): 715–725. doi:10.1093/infdis/jiv023. PMID 25601942.
  14. ^ "Slow off the starting blocks for Bharat Biotech's Covaxin mass production". The New Indian Express. 17 May 2021. Retrieved 4 June 2021.
  15. ^ "ICMR teams up with Bharat Biotech to develop Covid-19 vaccine". Livemint. 9 May 2020. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  16. ^ Chakrabarti, Angana (10 May 2020). "India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech". ThePrint. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  17. ^ "India's First COVID-19 Vaccine Candidate Approved for Human Trials". The New York Times. 29 June 2020. Archived from the original on 2 July 2020. Retrieved 30 June 2020.
  18. ^ "Human trial of India coronavirus vaccine announced". BBC News. 30 June 2020. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  19. ^ "Bharat Biotech's Covid vaccine 1st in India to get approval for human trials". The Indian Express. 30 June 2020. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  20. ^ "Covaxin: India's first COVID19 vaccine candidate from Bharat Biotech to begin human trials; check details". The Financial Express. 30 June 2020. Archived from the original on 3 May 2021. Retrieved 30 June 2020.
  21. ^ "Bharat Biotech COVID-19 vaccine: Testing underway at CDL-Kasauli, volunteer enrolment begins". Moneycontrol. Archived from the original on 10 July 2020. Retrieved 10 July 2020.
  22. ^ "Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS". DD News. Prasar Bharati, Ministry of I & B, Government of India. 25 July 2020. Archived from the original on 24 January 2021. Retrieved 7 August 2020.
  23. ^ "Delhi: 30-year-old is first to get dose of trial drug Covaxin". The Indian Express. 25 July 2020. Archived from the original on 16 March 2021. Retrieved 7 August 2020.
  24. ^ "COVID-19 | Office of Technology Management/Tech Transfer | Washington University in St. Louis".
  25. ^ "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine". The Indian Express. 23 September 2020. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
  26. ^ "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". NDTV.com. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
  27. ^ "COVID-19: Covaxin Vaccine Approved For Children Between 2 to 18". The Live Mirror. 12 October 2021. Retrieved 12 October 2021.
  28. ^ Das, Krishna N. (1 March 2021). "Chinese hackers target Indian vaccine makers SII, Bharat Biotech, says security firm". Reuters. Archived from the original on 3 May 2021. Retrieved 1 March 2021.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Bharat_Biotech&oldid=1053398796"